3.15 USD
▲+0.20+6.78%
盘后 2.90 -1.69%
2026-08-03
市值
$291.92M
市盈率
—
EPS
-0.39
股息率
—
52 周区间
2.26 – 11.70
成交量
1.98M
Beta
1.14
目标价
20.00
52W 低 2.2652W 高 11.70
价格走势
公司简介
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ...